Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease
임주현, 김상균, 송지현, 황재진, 이동호, 한재필, 홍수진, 김지현, 전성우, 김광하, 심기남, 신운건, 김태호, 김선문, 정일권, 김현수, 김흥업, 이중엽, 김재규,
소속 상세정보
임주현 ( Lim Joo-Hyun )
Seoul National University Hospital Department of Internal Medicine
김상균 ( Kim Sang-Gyun )
Seoul National University College of Medicine Department of Internal Medicine
송지현 ( Song Ji-Hyun )
Seoul National University Hospital Department of Internal Medicine
황재진 ( Hwang Jae-Jin )
Seoul National University Bundang Hospital Department of Internal Medicine
이동호 ( Lee Dong-Ho )
Seoul National University Bundang Hospital Department of Internal Medicine
한재필 ( Han Jae-Pil )
Soonchunhyang University College of Medicine Department of Internal Medicine
홍수진 ( Hong Su-Jin )
Soonchunhyang University College of Medicine Department of Internal Medicine
김지현 ( Kim Ji-Hyun )
Inje University College of Medicine Department of Internal Medicine
전성우 ( Jeon Seong-Woo )
Kyungpook National University School of Medicine Department of Internal Medicine
김광하 ( Kim Gwang-Ha )
Pusan National University School of Medicine Department of Internal Medicine
심기남 ( Shim Ki-Nam )
Ewha Womans University School of Medicine Department of Internal Medicine
신운건 ( Shin Woon-Geon )
Hallym University College of Medicine Department of Internal Medicine
김태호 ( Kim Tae-Ho )
Catholic University College of Medicine Department of Internal Medicine
김선문 ( Kim Sun-Moon )
Konyang University College of Medicine Department of Internal Medicine
정일권 ( Chung Il-Kwon )
Soonchunhyang University College of Medicine Soonchunhyang University Cheonan Hospital Department of Internal Medicine
김현수 ( Kim Hyun-Soo )
Chonnam National University Medical School Department of Internal Medicine
김흥업 ( Kim Heung-Up )
Jeju National University School of Medicine Department of Internal Medicine
이중엽 ( Lee Joong-Yub )
Seoul National University Hospital Medical Research Collaborating Center
김재규 ( Kim Jae-Gyu )
Chung-Ang University College of Medicine Department of Internal Medicine
KMID : 1188320170110020226
Abstract
Background/Aims: The resistance rate of Helicobacter pylori is gradually increasing. We aimed to evaluate the efficacy of levofloxacin-based third-line H. pylori eradication in peptic ulcer disease.
Methods: Between 2002 and 2014, 110 patients in 14 medical centers received levofloxacin-based third-line H. pylori eradication therapy for peptic ulcer disease. Of these, 88 were included in the study; 21 were excluded because of lack of follow-up and one was excluded for poor compliance. Their eradication rates, treatment regimens and durations, and types of peptic ulcers were analyzed.
Results: The overall eradiation rate was 71.6%. The adherence rate was 80.0%. All except one received a proton-pump inhibitor, amoxicillin, and levofloxacin. One received a proton-pump inhibitor, amoxicillin, levofloxacin, and clarithromycin, and the eradication was successful. Thirty-one were administered the therapy for 7 days, 25 for 10 days, and 32 for 14 days. No significant differences were observed in the eradication rates between the three groups (7-days, 80.6% vs 10-days, 64.0% vs 14-days, 68.8%, p=0.353). Additionally, no differences were found in the eradiation rates according to the type of peptic ulcer (gastric ulcer, 73.2% vs duodenal/gastroduodenal ulcer, 68.8%, p=0.655).
Conclusions: Levofloxacin-based third-line H. pylori eradication showed efficacy similar to that of previously reported first/second-line therapies.
키워드
Levofloxacin; Helicobacter pylori; Third-line eradication
원문 및 링크아웃 정보
등재저널 정보